Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesSolitary Fibrous Tumors of the Pleura: An Analysis of 110 Patients Treated in a Single Institution
Annals of Thoracic Surgery, 10/23/09
Cardillo G et al. – Solitary fibrous tumor of the pleura is a rare disease that includes both benign and malignant variants.The outcome is mostly benign, with an overall 10–year survival rate of 97.5%. Pathologically benign lesions show a better disease–free survival rate than malignant lesions. Surgery is the gold standard of treatment as neither radiotherapy nor chemotherapy proved to be effective.
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
New Advances in the Second-Line Treatment of Small Cell Lung Cancer
The Oncologist, 10/28/09
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Sponsor
Article Search
Sponsor